Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in
chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.